Abstracts tagged "severity and systemic lupus erythematosus (SLE)"

Abstract Number: 1694 • 2018 ACR/ARHP Annual Meeting
The Lupus Severity Index Accurately Identifies Patients with Severe SLE in a Multi-Ethnic Cohort
Christine A. Peschken¹, Carol Hitchon², David Robinson³, Ada Man³, Annaliese Tisseverasinghe³ and Hani El-Gabalawy², ¹RR 149G, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Rheumatology, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The Lupus Severity Index (LSI)* was recently proposed to stratify patients by disease severity for clinical research. The LSI ranges from 0-10, is calculated…
Abstract Number: 1077 • 2014 ACR/ARHP Annual Meeting
A Real-World Characterization of US Patients with “Moderate-to-Severe” Systemic Lupus Erythematosus
Vibeke Strand¹, Jennifer Johnson², Carl Vandeloo³, Catrinel Galateanu³ and Steve Lobosco², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Adelphi Real World Ltd., Macclesfield, United Kingdom, ³UCB Pharma, Brussels, Belgium
Background/Purpose Systemic lupus erythematosus (SLE) is a chronic, inflammatory disease which can impact on patients' Health-Related Quality of Life (HRQoL). This analysis was designed to…
Abstract Number: 1406 • 2012 ACR/ARHP Annual Meeting
The Cost of Management of Adult Active Systemic Lupus Erythematosus in the UK
Munther A. Khamashta¹, Christina Donatti², Ian N. Bruce³, Caroline Gordon⁴, David A. Isenberg⁵ and Ateka-Barrutia Oier⁶, ¹Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²Health Economics and Outcomes Research, IMS Health, United Kingdom, ³Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁴Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁶Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Several international studies have shown that systemic lupus erythematosus (SLE) has a considerable financial burden on patients and the health-care economy. Little recent information…
Abstract Number: 933 • 2012 ACR/ARHP Annual Meeting
Economic Burden of Systemic Lupus Erythematosus by Flare Severity in a Commercially Insured Population in the United States
Siva Narayanan¹, Emily Durden², Alan Oglesby³, Paul Juneau⁴ and Kathleen L. Wilson⁵, ¹Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ²Thomson Reuters, Austin, TX, ³GlaxoSmithKline, Research Triangle Park, NC, ⁴Truven Health Analytics, Washington, DC, ⁵Thomson Reuters Healthcare, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with an unpredictable disease course with sporadic periods of illness (flares). Little is known about…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].